2:59 PM ET
10-Q
Financial Results
Provectus Biopharmaceuticals Q3 2026 Results: Net Loss of $1.27M, Loss Narrows
Provectus Biopharmaceuticals reported a net loss of $3.56 million for the nine months ended September 30, 2026, compared to a $4.34 million loss in the prior year period. The company remains in the development stage with no revenue from drug candidates and is currently operating with a significant stockholders' deficit of $6.68 million.
- Key figure
- Net loss $1.27M